Available Technologies

Executive Summary

Early detection of Alzheimer’s disease (AD) is currently still difficult and inconclusive. New, non-invasive diagnostic tools to diagnose this widespread disease are heavily researched, as earlier and better diagnostics will alleviate many stressors for the patient and improve treatment options. Researchers at MSU have identified a new promising biomarker. This biomarker can be easily detected in the cerebrospinal fluid of patients, and can help rule out other causes of cognitive impairment.

Description of Technology

Amyloid beta peptide is a hallmark peptide in the etiology of AD. It has been shown that AD patients exhibit enhanced levels of glycopeptides compared to non-AD patients. MSU researchers now identified the exact structure of an amyloid beta glycopeptide. This novel biomarker can be used to allow earlier, more sensitive and empowered detection of AD.

Key Benefits

• Early detection of Alzheimer’s disease
• Higher diagnostic accuracy
• Possible exclusion of other causes of cognitive impairment

Applications

• Biomarker diagnostics for Alzheimer’s disease

Patent Status: 

Under review

Licensing Rights Available

Full licensing rights available

Inventors: Xuefei Huang, Peng Wang, Goran Larson, Jonas Nilsson

Tech ID: TEC2013-0117

Alternative contact due to temporary leave:

Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829.